NDLI: Practical management of patients with myelofibrosis receiving ruxolitinib.

Please wait, while we are loading the content...

Year: 2017 Volume: 10

Year: 2017

Year: 2013 Volume: 6 Issue: 6

Year: 2013 Volume: 6 Issue: 5

Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.

Practical management of patients with myelofibrosis receiving ruxolitinib.

The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches.

Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia.

Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice?

The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.

Treatment for hemophilia: recombinant versus plasma-derived coagulation factors - controversy and debate forever? An ethical medical challenge?

The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment.

Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.

Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?

Myelodysplastic syndromes: toward a risk-adapted treatment approach.

Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes.

Thrombosis in pediatric cancer: identifying the risk factors to improve care.

Year: 2013 Volume: 6 Issue: 4

Year: 2013 Volume: 6 Issue: 3

Year: 2013 Volume: 6 Issue: 2

Year: 2013 Volume: 6 Issue: 1

Practical management of patients with myelofibrosis receiving ruxolitinib.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Harrison, Claire Mesa, Ruben Ross, David Mead, Adam Keohane, Clodagh Gotlib, Jason Verstovsek, Srdan
Description	Country affiliation: United kingdom Author Affiliation: Harrison C ( Guy's and St. Thomas' NHS Foundation Trust, London, UK.)
Abstract	Myelofibrosis (MF) is characterized by bone marrow fibrosis, progressive anemia and extramedullary hematopoiesis, primarily manifested as splenomegaly. Patients also experience debilitating constitutional symptoms, including sequelae of splenomegaly, night sweats and fatigue. Ruxolitinib (INC424, INCB18424, Jakafi, Jakavi), a JAK1 and JAK2 inhibitor, was approved in November 2011 by the US FDA for the treatment of intermediate- or high-risk MF, and more recently in Europe and Canada for the treatment of MF-related splenomegaly or symptoms. These approvals were based on data from two randomized Phase III studies: COMFORT-I randomized against placebo, and COMFORT-II randomized against best available therapy. In these studies, ruxolitinib rapidly improved multiple disease manifestations of MF, reducing splenomegaly and improving quality of life of patients and potentially prolonging survival. However, as with other chemotherapies, ruxolitinib therapy is associated with some adverse events, such as anemia and thrombocytopenia. The aims of this article are to provide a brief overview of ruxolitinib therapy, to discuss some common adverse events associated with ruxolitinib therapy and to provide clinical management recommendations to maximize patients' benefit from ruxolitinib.
File Format	HTM / HTML
ISSN	17474086
Issue Number	5
Volume Number	6
e-ISSN	17474094
Journal	Expert Review of Hematology
Language	English
Publisher	Taylor & Francis
Publisher Date	2013-10-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Hematology Janus Kinases Antagonists & Inhibitors Primary Myelofibrosis Drug Therapy Protein Kinase Inhibitors Therapeutic Use Pyrazoles Humans Adverse Effects Treatment Outcome Journal Article Research Support, Non-u.s. Gov't Review
Content Type	Text
Resource Type	Article
Subject	Hematology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Ruxolitinib for myelofibrosis--an update of its clinical effects.

Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.

Ruxolitinib for the treatment of primary myelofibrosis.

Ruxolitinib: a new treatment option for myelofibrosis.

Practical management of myelofibrosis with ruxolitinib.

Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.

Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy.

Practical management of patients with myelofibrosis receiving ruxolitinib.

Similar Documents

Ruxolitinib for myelofibrosis--an update of its clinical effects.

Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.

Ruxolitinib for the treatment of primary myelofibrosis.

Ruxolitinib: a new treatment option for myelofibrosis.

Practical management of myelofibrosis with ruxolitinib.

Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.

Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy.

Practical management of patients with myelofibrosis receiving ruxolitinib.